Obstructive Hypertrophic Cardiomyopathy
Conditions
Brief summary
Change in myocardial perfusion reserve (MPR) (averaged values across all hypertrophied myocardial segments without significant LGE) from baseline to 2 years after initiation of treatment.
Detailed description
Change in MPR from BL to 12 weeks, Change in MPR from BL to 1 year, Changes in T1, T2 and extracellular volume (ECV) mapping from BL to 12 w, 1 year and 2 years, Change in LGE extent from BL to 12 w, 1 year and 2 years, Change in stroke work, ventricular efficiency, contractility, and arterial elastance assessed by P-V-loop-analysis from BL to 12 w, 1 year and 2 years, Change in kinetic energy and regional pressure gradients assessed by 4D flow-analysis from BL to 12 w, 1 year and 2 years, Changes in myocardial mass and left atrial volume assessed by standard CMR from BL to 12 w, 1 year and 2 years
Interventions
DRUGCAMZYOS 10 mg hard capsules
Sponsors
Region Skane
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change in myocardial perfusion reserve (MPR) (averaged values across all hypertrophied myocardial segments without significant LGE) from baseline to 2 years after initiation of treatment. | — |
Secondary
| Measure | Time frame |
|---|---|
| Change in MPR from BL to 12 weeks, Change in MPR from BL to 1 year, Changes in T1, T2 and extracellular volume (ECV) mapping from BL to 12 w, 1 year and 2 years, Change in LGE extent from BL to 12 w, 1 year and 2 years, Change in stroke work, ventricular efficiency, contractility, and arterial elastance assessed by P-V-loop-analysis from BL to 12 w, 1 year and 2 years, Change in kinetic energy and regional pressure gradients assessed by 4D flow-analysis from BL to 12 w, 1 year and 2 years, Changes in myocardial mass and left atrial volume assessed by standard CMR from BL to 12 w, 1 year and 2 years | — |
Outcome results
None listed